沙美特罗氟替卡松联合小剂量红霉素治疗支气管扩张症的临床疗效评价

Clinical efficacy of salmeterol and fluticasone combined with low-dose erythromycin in the treatment of bronchiectasis

目的探讨沙美特罗替卡松联合小剂量红霉素治疗支气管扩张症的临床治疗效果。方法选取2016年3月~2017年3月在本院诊治的76例支气管扩张症患者为研究对象,采用抽签法将所有研究对象随机分为对照组与观察组,各38例,予以对照组患者沙美特罗替卡松雾化吸入治疗,观察组在对照组的基础上联合小剂量红霉素口服治疗。比较两组研究对象的临床治疗效果和肺功能变化指标。结果观察组临床治疗总有效率为97.37%,显著高于对照组81.58%(c2=5.029,P<0.05);观察组治疗后的各项肺功能评分分别为(4.36±0.27)、(4.28±0.46)和(4.41±0.22),对照组为(3.35±0.42)、(3.27±0.51)和(3.71±0.35),观察组治疗后的肺功能指标显著优于对照组,差异具有统计学意义(t=9.046、t=6.577、t=7.573,P<0.05)。结论利用沙美特罗氟替卡松联合小剂量红霉素治疗支气管扩张,能够显著提升临床治疗效果,改善患者的各项肺功能指标,其临床应用价值较高。

Objective To investigate the clinical effect of salmeterol and ticalaprost in combination with low-dose erythromycin in the treatment of bronchiectasis. Methods A total of 76 patients with bronchiectasis treated in our hospital from March 2016 to March 2017 were enrolled in this study. All the subjects were randomized into control group and observation group, patients with salmeterol and ticarcus inhalation therapy, the observation group on the basis of the control group combined with low-dose erythromycin oral treatment. The clinical effects and indexes of lung function in two groups were compared. Results The total effective rate of the observation group was 97.37%, significantly higher than that of the control group 81.58%（c2=5.029, P〈0.05）. The pulmonary function scores of the observation group after treatment were（4.36±0.27）,（4.28±0.46） and（4.41±0.22） in the control group and（3.35±0.42） and（3.27±0.51） and（3.71±0.35） in the control group respectively. The pulmonary function indexes in the observation group were significantly better than those in the control group（t=9.046, t=6.577, t=7.573, P〈0.05）. Conclusion The use of salmeterol fluticasone in combination with low-dose erythromycin in the treatment of bronchiectasis can significantly improve the clinical effect and improve the pulmonary function of patients with high clinical value.